CancerDrs

Head and Neck Cancer clinical trials in Arizona

26 actively recruiting head and neck cancer trials at 9 sites across Arizona.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 1 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll.

Phase 3 Recruiting Industry

A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

The purpose of this study is to compare anti-tumor activity of amivantamab in addition to pembrolizumab and carboplatin versus pembrolizumab, 5-fluorouracil (FU), and platinum therapy (carboplatin or cisplatin) in participants with refract…

Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07276399
Sites in Arizona:
  • Ironwood Cancer and Research Center — Chandler, Arizona
  • University of Arizona Cancer Center — Tucson, Arizona
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma

The goal of this study is to understand whether CRB-701, a targeted form of chemotherapy called an anti-body drug conjugate, will work as a treatment for oropharyngeal (throat, tonsil) cancer. In patients who have already received platinum…

Sponsor: Corbus Pharmaceuticals Inc.
NCT ID: NCT07768189
Sites in Arizona:
  • The University of Arizona Cancer Center — Tucson, Arizona
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma

The purpose of this study is to compare the efficacy and safety of ficlatuzumab plus cetuximab compared to placebo plus cetuximab in participants with recurrent/metastatic (R/M) HPV-negative Head and Neck Cancer. The primary hypothesis is …

Sponsor: AVEO Pharmaceuticals, Inc.
NCT ID: NCT06064877
Sites in Arizona:
  • Banner MD Anderson Cancer Center — Gilbert, Arizona
  • The University of Arizona Cancer Center — Tucson, Arizona
View on ClinicalTrials.gov →
Phase 2 Recruiting Network

Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

This phase II trial studies how well radiation therapy with or without cisplatin works in treating patients with stage III-IVA squamous cell carcinoma of the head and neck who have undergone surgery. Radiation therapy uses high energy x-ra…

Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT02734537
Sites in Arizona:
  • Cancer Center at Saint Joseph's — Phoenix, Arizona
  • University of Arizona Cancer Center-Orange Grove Campus — Tucson, Arizona
  • Banner University Medical Center - Tucson — Tucson, Arizona
  • University of Arizona Cancer Center-North Campus — Tucson, Arizona
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer

This phase II trial tests the addition of chemotherapy, with carboplatin and paclitaxel, or chemo-immunotherapy, with carboplatin, paclitaxel and cemiplimab to standard salvage surgery followed by post operative radiation therapy and cispl…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07195734
Sites in Arizona:
  • Banner University Medical Center - Tucson — Tucson, Arizona
  • University of Arizona Cancer Center-North Campus — Tucson, Arizona
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)

This study, the first clinical trial of AVZO-1418, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and antitumor activity of AVZO-1418 when administered intravenously as a monotherapy…

Sponsor: Avenzo Therapeutics, Inc.
NCT ID: NCT07038343
Sites in Arizona:
  • Avenzo Therapeutics Recruiting Site — Gilbert, Arizona
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

The goal of this study is to test A2B395, an allogeneic logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC)…

Sponsor: A2 Biotherapeutics Inc.
NCT ID: NCT06682793
Sites in Arizona:
  • Banner MD Anderson Cancer Center — Gilbert, Arizona
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States

The purpose of this study is to characterize the clinical effects of tislelizumab, including pharmacokinetics (PK), activity, and safety assessments in US racial and ethnic minority patients with human epidermal growth factor receptor 2 (H…

Sponsor: BeOne Medicines
NCT ID: NCT07554521
Sites in Arizona:
  • Pioneer Research Center — Bullhead City, Arizona
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)

This is a phase 1/2, multicenter, open-label umbrella platform study that will evaluate the safety and tolerability of investigational agents with pembrolizumab and fluoropyrimidine chemotherapy for the first-line (1L) treatment of partici…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06469944
Sites in Arizona:
  • University of Arizona Cancer Center-University of Arizona Cancer Center ( Site 6927) — Tucson, Arizona
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study to Investigate ALE.P02 as a Monotherapy or in Combination With Pembrolizumab in Adult Patients With Selected CLDN1+ Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic, preliminary anti-tumor activity, and to determine the recommended Phase II dose (RP2D) of the ALE.P02 as a monotherapy or in combination w…

Sponsor: Alentis Therapeutics AG
NCT ID: NCT06747585
Sites in Arizona:
  • Mayo Foundation for Medical Education and Research - Mayo Cl — Scottsdale, Arizona
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067

This is a multiphase, multicenter study, which includes a Phase 1a open-label, dose escalation monotherapy study of ST-067 given as an SC injection with or without obinutuzumab \[Gazyva®\] pre-treatment, by IV infusion, and in combination …

Sponsor: Simcha IL-18, Inc.
NCT ID: NCT04787042
Sites in Arizona:
  • HonorHealth Research Institute — Scottsdale, Arizona
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

This is a Phase 1/2a, open-label, study to evaluate the safety and preliminary efficacy of intratumoral T3011 given alone and in combination with intravenous pembrolizumab in partients with advanced or metastatic solid tumors.

Sponsor: ImmVira Pharma Co. Ltd
NCT ID: NCT04370587
Sites in Arizona:
  • Banner MD Anderson Cancer Center — Gilbert, Arizona
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)

This is a Phase 1/2, multicenter, randomized, open-label umbrella platform study to evaluate the safety and efficacy of investigational agents with or without pembrolizumab and/or chemotherapy, for the treatment of participants with second…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT05319730
Sites in Arizona:
  • University of Arizona Cancer Center-University of Arizona Cancer Center ( Site 4927) — Tucson, Arizona
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Academic/Other

Ph. I/II Sodium Thiosulfate for OtoProtection During Cisplatin (STOP-CIS)

The purpose of this study is to assess the safety and effectiveness of a drug called Pedmark® sodium thiosulfate (STS) in reducing hearing impairment with standard of care cisplatin therapy. The safety and effectiveness of STS in reducing …

Sponsor: University of Arizona
NCT ID: NCT07407582
Sites in Arizona:
  • University of Arizona Cancer Center — Tucson, Arizona
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alon…

Sponsor: Exelixis
NCT ID: NCT05176483
Sites in Arizona:
  • Exelixis Clinical Site #67 — Phoenix, Arizona
  • Exelixis Clinical Site #1 — Tucson, Arizona
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

This is a multicenter clinical study to evaluate the safety, efficacy, and Pharmacokinetics (PK) of IDE892 as monotherapy and in combination with other agents including IDE397 in participants with methylthioadenosine phosphorylase (MTAP)-d…

Sponsor: IDEAYA Biosciences
NCT ID: NCT07277413
Sites in Arizona:
  • City of Hope Cancer Center-Phoenix — Goodyear, Arizona
  • Mayo Clinic Arizona — Phoenix, Arizona
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors

The main purpose of this study is to evaluate the safety and preliminary efficacy of CHS-114 in combination with toripalimab and/or other standard of care (SOC) compound(s) in participants with advanced or metastatic solid tumors.

Sponsor: Coherus Oncology, Inc.
NCT ID: NCT06657144
Sites in Arizona:
  • The University of Arizona Cancer Center — Tucson, Arizona
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors

The study will assess the safety, PK, PD, and preliminary efficacy of ABBV-CLS-484 as monotherapy and in combination with a PD-1 targeting agent or with a or a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (…

Sponsor: Calico Life Sciences LLC
NCT ID: NCT04777994
Sites in Arizona:
  • University of Arizona Cancer Center - Tucson /ID# 262698 — Tucson, Arizona
View on ClinicalTrials.gov →
Phase 1 Recruiting Academic/Other

A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors

Part 1 of this study is an open-label, dose-escalation, and safety expansion study of an anti-LILRB2 / anti-PD-L1 bispecific antibody SPX- 303 in patients with solid tumors. Part 2 of this study is an indication-specific dose expansion stu…

Sponsor: SparX Biotech(Jiangsu) Co., Ltd.
NCT ID: NCT06259552
Sites in Arizona:
  • Mayo Clinic Arizona — Phoenix, Arizona
  • HonorHealth Research and Innovation Institute — Scottsdale, Arizona
View on ClinicalTrials.gov →
Recruiting Academic/Other

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Arizona:
  • Kingman Regional Medical Center — Kingman, Arizona
  • Cancer Center at Saint Joseph's — Phoenix, Arizona
View on ClinicalTrials.gov →
NA Recruiting Academic/Other

Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays

This clinical trial is being done to learn whether using the proactive, graduated dose modification algorithm for leucovorin, 5-fluorouracil (5-FU), and oxaliplatin (FOLFOX) (PAGODA) algorithm to guide chemotherapy dosing for the FOLFOX re…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07283939
Sites in Arizona:
  • Cancer Center at Saint Joseph's — Phoenix, Arizona
View on ClinicalTrials.gov →
Recruiting Industry

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…

Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Arizona:
  • Massive Bio SYNERGY-AI site — Scottsdale, Arizona
View on ClinicalTrials.gov →
Recruiting Industry

DESTINY-PANTUMOUR04

This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease and have n…

Sponsor: AstraZeneca
NCT ID: NCT07124000
Sites in Arizona:
  • Research Site — Bullhead City, Arizona
  • Research Site — Casa Grande, Arizona
View on ClinicalTrials.gov →

Showing 25 of 26 trials with sites in Arizona. See all head and neck cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-11-09